Drug name - Erivedge

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7888364 GENENTECH Pyridyl inhibitors of hedgehog signalling
Nov, 2028

(6 years from now)

CN101072755A GENENTECH Pyridyl Inhibitor Transduced By Hedgehog Signal
Sep, 2012

(10 years ago)

EP1789390B1 GENENTECH Pyridyl Inhibitors Of Hedgehog Signalling
Jul, 2028

(5 years from now)

EP1789390A2 GENENTECH Pyridyl Inhibitors Of Hedgehog Signalling
Jul, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9790183 GENENTECH Pyridyl inhibitors of hedgehog signalling Sep, 2025

(2 years from now)

US9278961 GENENTECH Pyridyl inhibitors of hedgehog signalling Dec, 2028

(6 years from now)

Drugs and Companies using VISMODEGIB ingredient

Treatment: Method of using vismodegib to treat basal cell carcinoma; Method of using vismodegib to treat cancer in a mammal

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
150MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.